The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
What Will Be The Estimated Market Size Of The Rhinovirus Infections Drug Market By 2030?
The market size for rhinovirus infections drugs has demonstrated significant expansion in recent years. This sector is anticipated to increase from $1.36 billion in 2025 to $1.48 billion in 2026, registering a compound annual growth rate (CAGR) of 8.8%. The expansion observed historically can be attributed to several factors, including the high incidence of the common cold, the limited availability of antiviral treatment options, widespread consumption of over-the-counter medications, characteristic seasonal infection trends, and consumers’ desire for quick relief.
The rhinovirus infections drug market is projected for significant expansion in the coming years. This market is set to reach $2.05 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 8.6%. Factors driving this growth during the projection period include advancements in antiviral research, enhanced viral targeting technologies, increased awareness of respiratory infections, progress in pediatric drug development, and innovations in nasal delivery methods. Key trends anticipated for the forecast period encompass intensified research into antiviral treatments for the common cold, a greater emphasis on therapies aimed at symptom reduction, an increase in nasal spray formulations, heightened interest in immune-modulating medications, and a movement towards preventive respiratory care.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=23503&type=smp
Which Significant Factors Are Encouraging Growth In The Rhinovirus Infections Drug Market?
A rising occurrence of respiratory ailments is projected to boost the expansion of the rhinovirus infections drug market in the future. These disorders are medical conditions impacting the lungs and airways, resulting in breathing difficulties, including conditions like asthma, chronic obstructive pulmonary disease (COPD), and pneumonia. The surge in respiratory disorders stems largely from elevated air pollution and exposure to workplace dangers, contributing to the greater prevalence of conditions such as asthma, COPD, and pneumonia among vulnerable populations. Drugs for rhinovirus infections aid respiratory disorders by targeting viral multiplication, diminishing inflammation, and easing symptoms, thereby enhancing respiratory function. As an illustration, in June 2025, the Office for Health Improvement & Disparities, a UK-based government agency, reported that England registered 854,922 emergency respiratory-related hospital admissions in the year ending 2024, at a rate of 1,428 per 100,000 people, representing a 7% increase compared to the prior year. Consequently, the growing frequency of respiratory illnesses fuels expansion in the rhinovirus infections drug market.
How Is The Rhinovirus Infections Drug Market Examined Through Segment Analysis?
The rhinovirus infections drug market covered in this report is segmented –
1) By Product: Antivirals, Immunomodulators, Vaccines, Nasal Sprays, Symptomatic Treatments
2) By Patient Age Group: Infants, Children, Adults, Elderly
3) By Route Of Administration: Oral, Intranasal, Injectable
4) By Indication: Common Cold, Asthma Exacerbation, Chronic Obstructive Pulmonary Disease (COPD) Exacerbation, Other Indications
5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Specialty Pharmacies
Subsegments:
1) By Antivirals: Pleconaril, Vapendavir, Rupintrivir, Other Antivirals
2) By Immunomodulators: Interferons, Toll-Like Receptor Agonists, Other Immunomodulators
3) By Vaccines: Live Attenuated Vaccines, Inactivated Vaccines, Recombinant Vaccines
4) By Nasal Sprays: Antihistamine Nasal Sprays, Decongestant Nasal Sprays, Steroid Nasal Sprays, Saline Nasal Sprays
5) By Symptomatic Treatments: Analgesics, Antipyretics, Cough Suppressants, Expectorants, Antihistamines
Which Trends Are Expected To Shape The Rhinovirus Infections Drug Market?
Leading companies within the rhinovirus infections drug market are concentrating on creating novel products, notably antiviral medications, with the goal of improving treatment effectiveness, lessening the intensity of symptoms, and speeding up patient recovery. These antiviral drugs function by stopping the replication of viruses inside the body, thereby treating viral infections. They are capable of managing conditions such as influenza, HIV, hepatitis, and rhinovirus. Certain antivirals work by preventing viruses from entering host cells, whereas others halt viral replication or assembly processes. An example of this trend is observed in March 2025, when Altesa BioSciences Inc., a biotechnology firm based in the US, secured approval from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application concerning vapendavir, intended for treating rhinovirus infections in individuals afflicted with COPD. Vapendavir is an oral broad-spectrum antiviral medication designed to stop rhinovirus from penetrating human cells and subsequently replicating. Its efficacy has been shown against 97% of rhinoviruses and various other respiratory enteroviruses. Altesa BioSciences possesses the exclusive worldwide rights for the development, manufacturing, and commercialization of vapendavir. This medication seeks to offer targeted therapeutic options for susceptible populations, specifically those suffering from COPD and asthma.
Who Are The Key Market Participants In The Rhinovirus Infections Drug Market?
Major companies operating in the rhinovirus infections drug market are Pfizer Inc., Teva Pharmaceutical Industries Ltd., Cocrystal Pharma Inc., Biota Pharmaceuticals Inc., Romark Laboratories L.C., Altamira Therapeutics Ltd., Pneumagen Ltd., AIM ImmunoTech Inc., hVIVO Services Limited, Maxwell Biosciences Inc., Altesa BioSciences Inc., Via Nova Therapeutics Inc., MetP Pharma AG, Ntvirin Pharma, GlaxoSmithKline plc, Johnson & Johnson, Sanofi S.A., Bayer AG, Cipla Limited, Reckitt Benckiser Group plc
Access The Complete Rhinovirus Infections Drug Market Report:
https://www.thebusinessresearchcompany.com/report/rhinovirus-infections-drug-global-market-report
Which Region Is The Dominant Market In The Rhinovirus Infections Drug Market?
North America was the largest region in the rhinovirus infection drug market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rhinovirus infections drug market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Rhinovirus Infections Drug Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/sample.aspx?id=23503&type=smp
Browse Through More Reports Similar to the Global Rhinovirus Infections Drug Market 2026, By The Business Research Company
Antiviral Combination Therapy Market Report 2026
https://www.thebusinessresearchcompany.com/report/antiviral-combination-therapy-global-market-report
Acne Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/acne-drugs-global-market-report
Respiratory Syncytial Virus Rsv Therapeutics Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model